 |
|
CLINICIAN'S CORNER
Antiretroviral Treatment of Adult HIV Infection2008 Recommendations of the International AIDS Society–USA Panel
Scott M. Hammer, MD;
Joseph J. Eron Jr, MD;
Peter Reiss, MD, PhD;
Robert T. Schooley, MD;
Melanie A. Thompson, MD;
Sharon Walmsley, MD;
Pedro Cahn, MD;
Margaret A. Fischl, MD;
Jose M. Gatell, MD, PhD;
Martin S. Hirsch, MD;
Donna M. Jacobsen, BS;
Julio S. G. Montaner, MD;
Douglas D. Richman, MD;
Patrick G. Yeni, MD;
Paul A. Volberding, MD
JAMA. 2008;300(5):555-570.
Context The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral-naive and -experienced patients warrant an update of the International AIDS Society–USA guidelines for the use of antiretroviral therapy in adult human immunodeficiency virus (HIV) infection.
Objectives To summarize new data in the field and to provide current recommendations for the antiretroviral management and laboratory monitoring of HIV infection. This report provides guidelines in key areas of antiretroviral management: when to initiate therapy, choice of initial regimens, patient monitoring, when to change therapy, and how best to approach treatment options, including optimal use of recently approved drugs (maraviroc, raltegravir, and etravirine) in treatment-experienced patients.
Data Sources and Study Selection A 14-member panel with expertise in HIV research and clinical care was appointed. Data published or presented at selected scientific conferences since the last panel report (August 2006) through June 2008 were identified.
Data Extraction and Synthesis Data that changed the previous guidelines were reviewed by the panel (according to section). Guidelines were drafted by section writing committees and were then reviewed and edited by the entire panel. Recommendations were made by panel consensus.
Conclusions New data and considerations support initiating therapy before CD4 cell count declines to less than 350/µL. In patients with 350 CD4 cells/µL or more, the decision to begin therapy should be individualized based on the presence of comorbidities, risk factors for progression to AIDS and non-AIDS diseases, and patient readiness for treatment. In addition to the prior recommendation that a high plasma viral load (eg, >100 000 copies/mL) and rapidly declining CD4 cell count (>100/µL per year) should prompt treatment initiation, active hepatitis B or C virus coinfection, cardiovascular disease risk, and HIV-associated nephropathy increasingly prompt earlier therapy. The initial regimen must be individualized, particularly in the presence of comorbid conditions, but usually will include efavirenz or a ritonavir-boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine). Treatment failure should be identified and managed promptly, with the goal of therapy, even in heavily pretreated patients, being an HIV-1 RNA level below assay detection limits.
Author Affiliations: Columbia University College of Physicians and Surgeons, New York, New York (Dr Hammer); University of North Carolina at Chapel Hill (Dr Eron); Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (Dr Reiss); University of California San Diego, La Jolla (Dr Schooley); AIDS Research Consortium of Atlanta, Atlanta, Georgia (Dr Thompson); University of Toronto, Toronto, Ontario, Canada (Dr Walmsley); Hospital Juan Fernandez/University of Buenos Aires Medical School and Fundacion Huesped, Buenos Aires, Argentina (Dr Cahn); University of Miami, Miami, Florida (Dr Fischl); University of Barcelona, Barcelona, Spain (Dr Gatell); Harvard Medical School, Boston, Massachusetts (Dr Hirsch); International AIDS Society–USA (Ms Jacobsen) and University of California San Francisco and San Francisco Veterans Affairs Medical Center (Dr Volberding), San Francisco; University of British Columbia, Vancouver, British Columbia, Canada (Dr Montaner); University of California San Diego and Veterans Affairs San Diego Healthcare System, San Diego (Dr Richman); and Hôpital Bichat-Claude Bernard and Xavier Bichat Medical School, Paris, France (Dr Yeni).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Therapy Recommendations for HIV-Associated Neurocognitive Disorders
JAMA. ;300():2482-2482.
FULL TEXT
Therapy Recommendations for HIV-Associated Neurocognitive Disorders--Reply
and
JAMA. ;300():2482-2483.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Factors influencing lopinavir and atazanavir plasma concentration
Stohr et al.
J Antimicrob Chemother 2009;0:dkp408v1-dkp408.
ABSTRACT
| FULL TEXT
Efavirenz: a decade of clinical experience in the treatment of HIV
Maggiolo
J Antimicrob Chemother 2009;64:910-928.
ABSTRACT
| FULL TEXT
Inhibition of Envelope-Mediated CD4+-T-Cell Depletion by Human Immunodeficiency Virus Attachment Inhibitors
Alexander et al.
Antimicrob. Agents Chemother. 2009;53:4726-4732.
ABSTRACT
| FULL TEXT
Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients
Genebat et al.
J Antimicrob Chemother 2009;64:845-849.
ABSTRACT
| FULL TEXT
Dynamic Host Energetics and Cytoskeletal Proteomes in Human Immunodeficiency Virus Type 1-Infected Human Primary CD4 Cells: Analysis by Multiplexed Label-Free Mass Spectrometry
Chan et al.
J. Virol. 2009;83:9283-9295.
ABSTRACT
| FULL TEXT
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting
Zazzi et al.
J Antimicrob Chemother 2009;64:616-624.
ABSTRACT
| FULL TEXT
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
Belanger et al.
Drug Metab. Dispos. 2009;37:1793-1796.
ABSTRACT
| FULL TEXT
Plasma citrulline is a biomarker of enterocyte mass and an indicator of parenteral nutrition in HIV-infected patients
Crenn et al.
Am. J. Clin. Nutr. 2009;90:587-594.
ABSTRACT
| FULL TEXT
Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation
Kwara et al.
J Clin Pharmacol 2009;49:1079-1090.
ABSTRACT
| FULL TEXT
Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2-/-{gamma}c-/- Mouse
Choudhary et al.
J. Virol. 2009;83:8254-8258.
ABSTRACT
| FULL TEXT
Cohorts, Trials, and Evidence: Expanding Our Confidence in Guidelines for Antiretroviral Resistance Testing
Volberding
ANN INTERN MED 2009;151:135-136.
FULL TEXT
Case 11-2009: A Man with Fever, Headache, Rash, and Vomiting
Del Borgo et al.
NEJM 2009;361:312-314.
FULL TEXT
Cardiovascular manifestations of HIV infection
Ho and Hsue
Heart 2009;95:1193-1202.
FULL TEXT
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
Landman et al.
J Antimicrob Chemother 2009;64:118-125.
ABSTRACT
| FULL TEXT
Overestimation of Human Immunodeficiency Virus Type 1 Load Caused by the Presence of Cells in Plasma from Plasma Preparation Tubes
Kran et al.
J. Clin. Microbiol. 2009;47:2170-2174.
ABSTRACT
| FULL TEXT
Considering the individual - principles of treatment choice
Waters
Int J STD AIDS 2009;20:2-6.
ABSTRACT
| FULL TEXT
Initiating and maintaining HAART - aiming for the long term in treatment-naive patients
Behrens
Int J STD AIDS 2009;20:7-11.
ABSTRACT
| FULL TEXT
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
Dinoso et al.
Proc. Natl. Acad. Sci. USA 2009;106:9403-9408.
ABSTRACT
| FULL TEXT
R964C Mutation of DNA Polymerase {gamma} Imparts Increased Stavudine Toxicity by Decreasing Nucleoside Analog Discrimination and Impairing Polymerase Activity
Bailey et al.
Antimicrob. Agents Chemother. 2009;53:2610-2612.
ABSTRACT
| FULL TEXT
When to Start Antiretroviral Therapy -- Ready When You Are?
Sax and Baden
NEJM 2009;360:1897-1899.
FULL TEXT
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata et al.
NEJM 2009;360:1815-1826.
ABSTRACT
| FULL TEXT
Case 11-2009 -- A 47-Year-Old Man with Fever, Headache, Rash, and Vomiting
Bell and Rosenberg
NEJM 2009;360:1540-1548.
FULL TEXT
Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests
Garrido et al.
J. Clin. Microbiol. 2009;47:1031-1036.
ABSTRACT
| FULL TEXT
Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Flaviviruses
Chang et al.
Antimicrob. Agents Chemother. 2009;53:1501-1508.
ABSTRACT
| FULL TEXT
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
Descamps et al.
J Antimicrob Chemother 2009;63:585-592.
ABSTRACT
| FULL TEXT
Excess mortality after HIV seroconversion has greatly decreased in the past 10 years
Moore
Evid. Based Med. 2009;14:23-23.
FULL TEXT
Therapy Recommendations for HIV-Associated Neurocognitive Disorders
Zirulnik
JAMA 2008;300:2482-2482.
FULL TEXT
A New Class of Anti-HIV Therapy and New Challenges
Dolin
NEJM 2008;359:1509-1511.
FULL TEXT
Treatment of HIV Infection: Updated Guidelines from the IAS-USA
JWatch Infect. Diseases 2008;2008:1-1.
FULL TEXT
New Guidelines Tweak Criteria for HIV Treatment
JWatch General 2008;2008:1-1.
FULL TEXT
|
